Compass Pathways reveals its timeline for psilocybin treatment’s new drug application, targeting commercial availability by 2027.

A Minnesota state analysis of 1,811 autism patients found sustained reductions in moderate-to-severe anxiety and depression after joining the medical cannabis program, with improvements often lasting at least four months.

Estrogen’s influence on serotonin and glutamate links women’s health to psychedelic care. Here’s what patients and DMV providers should understand now.

A small Johns Hopkins pilot gave two psilocybin doses to 20 adults with chronic Lyme symptoms. Participants reported improved sleep and quality of life, and a 40% symptom drop at six months.

A power shift at Lykos Therapeutics could revive MDMA-assisted therapy—and Rick Doblin’s influence. Here’s what’s changing, why it matters, and how DMV residents should watch the next moves.

NORML reports a decade-long study in back pain patients linking medical cannabis therapy to sustained pain relief and sharply reduced reliance on pharmaceuticals.

A University of Georgia analysis of 20M+ responses finds a 7% drop in health-related absences where medical cannabis is accessible, with strongest effects in physical jobs.

A look at non‑drug “technodelics” like mirrored chambers, strobe light journeys, and full‑body pods—and what early research suggests about benefits, safety, and limits.